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31 Background: The poor biopharmaceutical properties of thymoquinone (TQ) obstruct its 
32 development as a hepatoprotective agent. To surmount the delivery challenges of TQ, 
33 phospholipid nanoconstructs (PNCs) were constructed.
34 Method: PNCs were constructed employing microemulsification technique and systematic 
35 optimization by three-factor three level Box-Behnken design.
36 Result: Optimized PNC composition exhibited nano size (<100 nm), spherical morphology, 
37 within acceptable range of polydispersity index (0.55), high drug entrapment efficiency (>90%), 
38 controlled drug release pattern, and neutral surface charge (zeta potential of -0.65 mV). After oral 
39 administration of a single dose of PNC, it showed a relative bioavailability of 386.03% vis-à-vis 
40 plain TQ suspension. Further, TQ-loaded PNC demonstrated significant enhanced hepato-
41 protective effect vis-à-vis pure TQ suspension and silymarin, as evidenced by reduction in the 
42 ALP, ALT, AST, bilirubin and albumin level and ratified by histopathological analysis. 
43 Conclusion: TQ-loaded PNCs can be efficient nano-platforms for the management of hepatic 
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59 Liver diseases, especially viral hepatitis occurs predominately in developing countries with an 
60 enormous impact on public health and economy [1,2]. Liver diseases account for approximately 2 
61 million deaths per year worldwide [3]. Thymoquinone (TQ: 2-isopropyl-5-methylbenzo-1,4-
62 quinone), the main active molecule of Nigella sativa (NS) essential oil, is a promising contender 
63 for the prevention of hepatic diseases [4-6]. The hepatoprotective effects of TQ may be linked with 
64 its ameliorating effects on inflammation, apoptosis, and oxidative stress pathways. This 
65 subsequently results in the less transactivation of hepatic stellate cells (HSCs) [2,7,8]. Oral 
66 administration of TQ alleviates oxidative stress in liver mucosa directly via its free radical 
67 scavenging action and/or indirectly via stimulation of endogenous enzymatic and non-enzymatic 
68 antioxidants enzymes [9]. Further, TQ alleviates liver inflammation by inhibiting cyclooxygenase 
69 pathway and eicosanoid generation in leukocytes, and also 5-lipooxygenase and peroxidase [10]. 
70 Although, TQ is a potential candidate for treating hepatic diseases but its highly hydrophobic 
71 nature limits its oral bioavailability. The solubility of TQ in aqueous medium has been reported to 
72 be less than < 1.0 mg/mL at room temperature. Further, it is also reported to have degradation in 
73 the aqueous media and in the presence of light. These limitations can be overcome by strategically 
74 formulating nanosized formulation of TQ such as phospholipid nanoconstructs, which can protect 
75 the encapsulated drug, enhance the bioavailability, passively-target the drug to the liver, and 
76 release the drug in a controlled and effective manner. 
77 Phospholipid based nanocarrier systems could be a potential delivery system for enhancing 
78 solubility and therapeutic efficacy (11). Presently, researchers are being focused to the 
79 development of newer delivery approaches to get enhanced benefit using TQ.
80 Kalam et al., 2017 evaluated the hepato-protective potential of TQ-loaded self-nanoemulsifying 
81 drug delivery systems (SNEDDS) using CCl4 induced hepato-toxicity model. Results indicated the 
82 significant hepatoprotective effects for optimized TQ-loaded SNEDDS vis-à-vis TQ suspension. 
83 The comparative bioavailability of TQ was enhanced 3.87-fold by optimized SNEDDS in 
84 comparison with TQ suspension. (Singh et al., 2013) evaluated the hepato-protective potential of 
85 TQ-loaded solid lipid nanoparticles (SLNs) against Paracetamol-induced hepatotoxicity. Findings 
86 revealed that TQ-SLNs significantly reduced the serum biomarker enzymes (SGOT, SGPT and 
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87 ALP) compared to pure TQ suspension. Further, in vivo studies revealed a nearly 5-fold increase 
88 in the bioavailability of TQ-SLN as compared to pure TQ suspension.
89 Among various lipidic nanocarrier systems, a novel phospholipid based nanostructured lipid 
90 carriers (NLCs), composed of phospholipids, lipids, blend of surfactant/co-surfactant and water 
91 seen to be effective in accomplishing the therapeutic requirements of TQ. (Sayeed et al., 2017) 
92 prepared TQ-loaded proniosome based formulation for hepato-protective activity against 
93 methotrexate-induced hepato-toxicity. Findings revealed that TQ-loaded proniosomes 
94 significantly inhibited the elevated levels of liver enzymes, serum marker enzymes and improved 
95 histopathological abn rmalities [12].
96 NLCs, the second-generation of lipid carriers, are composed of a mixture of spatially different 
97 lipids, i.e., the blend of solid lipid and liquid lipid [13,14]. NLCs stimulate oral absorption of 
98 encapsulated drugs via selectiv  uptake through the lymphatic route or the payer’s patches [15-
99 17]. NLC formulations of TQ prepared by high shear homogenization and ultrasonication have 
100 earlier been reported to improve the therapeutic efficacy of the drug in animal models for the 
101 treatment of gastric ulcer [18] tumor [19] and hepatic disorders [9]. In comparison to the previously 
102 employed methods to prepare TQ-loaded NLCs, microemulsification method is simple, 
103 reproducible, no energy requirement, cost-effective and can be easily scaled-up. Moreover, NLCs 
104 with low particle size, narrow size distribution and high entrapment efficiency can be obtained. 
105 The combination of surfactants usually produces smaller particle sizes due to the surface-active 
106 property of the surfactants. Thus, in the present research work, we have attempted to incorporate 
107 phospholipid (i.e., Phospholipon 90G) as surfactant-co-surfactant mixture (Smix) with a non-ionic 
108 surfactant (i.e., Tween 80) so as to result in the construction of the phospholipid nanoconstructs 
109 (PNCs) employing microemulsification method. Phospholipon 90G is a Zwitterionic surfactant 
110 and is expected to enhance the biopharmaceutical performance and therapeutic efficacy of 
111 hydrophobic drug molecules. It tends to provide enhanced solubility and permeability of the drugs 
112 across the biological barriers, thus improving their oral biopharmaceutical performance owing to 
113 its amphiphilic nature. Additionally, phospholipids constitute a major part of the bio-membrane 
114 and thus enhance the cellular uptake of the drugs [20].
115 The best understanding of the product and process during the development of a formulation could 
116 be achieved employing design of experiments (DoE), which is an excellent tool to systematically 
117 manipulate factors according to a prespecified design [21]. Box-Behnken design (BBD), is one 
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118 such DoE response surface methodology design, having numerous design advantages in 
119 comparison to other second order designs, e.g., central composite design (CCD) [22-24]. Thus, in 
120 the present investigation, BBD was used to optimize the TQ-loaded PNCs. Solid lipid, liquid lipid 
121 and surfactant/co-surfactant blend i.e., (Smix): (T80:PL90G), were employed as the input variables 
122 for studying their effect on the responses like particle size and entrapment efficiency. The best-
123 optimized TQ-loaded PNC was then evaluated for in vitro release kinetics to study the release 
124 mechanism, pharmacokinetic assessment and hepato-protective activity in Paracetamol-induced 
125 hepato-toxicity model in Wistar rats. 
126 2. Materials and Methods 
127 2.1. Materials
128 TQ was purchased from M/s Sigma Aldrich, Mumbai, India. Phospholipon 90G (PL90G) was 
129 received ex gratis from M/s Phospholipid GmbH, Nattermannallee, Germany. Ethanol was 
130 purchased from M/s Merck Specialities Pvt. Ltd., Mumbai, India, while Span 80 and Tween 80 
131 from M/s Qualikem Fine Chemicals Pvt. Ltd. Vadodara, India, Glyceryl monostearate (GMS) and 
132 stearic acid were obtained from Hi-Media Pvt. Ltd., Mumbai, India, and Capmul was procured 
133 from, M/s Biochem Pharmaceutical Industries. Olive oil, castor oil and oleic acid were purchased 
134 from M/s Loba Chemie Pvt. Ltd., Mumbai, India.
135 Wistar rats (250-300 g) used in the current study were procured from Animal house facility of 
136 National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India and kept at 
137 the animal house establishment of Shoolini University, Solan, HP, India. Animal studies were 
138 conducted with prior approval of Institutional Animal Ethical Committee of Shoolini University 
139 (IAEC/SU/17/07). Rats were housed in plastic bottom cages and allowed free access to standard 
140 animal feed and water. The animals were maintained at a temperature of 25 ± 2 °C with relative 
141 humidity of 45 ± 5%. The animals were initially acclimatized to experimental laboratory 
142 conditions for 7 days before the experiments.
143 2.2. Screening of liquid lipids
144 Selection of various liquid lipids viz. olive oil, capmul, oleic acid, and castor oil was done based 
145 on their solubility in TQ. Direct exposure of the drug to sunlight was avoided by working carefully 
146 in a dark hood within the laboratory. About 10 mL of oil was placed in 15 mL culture tubes and 
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147 excess amount of TQ was added into it maintained at thermostatically controlled shaker water bath 
148 maintained at 37±1°C. Further, the weighed quantity of clear solution was dissolved in ethanol 
149 and analyzed spectrophotometrically after suitable dilution (s). 
150 2.3. Screening of solid lipids
151 Solubility studies for TQ were carried out in various lipids, viz. Compritol, stearic acid and GMS. 
152 Excess amount of drug was added into 100 mg of solid lipid taken in a 5 mL culture tube 
153 maintained at thermostatically controlled shaker water bath at 70±1°C to get a clear solution. 
154 Further, the weighed quantity of clear solution was dissolved in ethanol and analyzed 
155 spectrophotometrically after suitable dilution (s). Whole study was carried in a dark hood within 
156 the laboratory to protect the drug from direct exposure to sunlight. 
157 2.2. Preparation of PNCs
158 PNCs were constructed employing microemulsifcation technique with some modification. 
159 Initially, drug was dissolved in a portion of ethanol. The phospholipid was dispersed/dissolved in 
160 a portion of water along with Tween 80 to form the aqueous phase. Solid lipid was melted at 70°C 
161 and liquid lipid was completely mixed with it. Subsequently, lipid phase, aqueous phase and drug 
162 solution were mixed isothermally to obtain a clear microemulsion. The remaining portion of water 
163 was cooled at 4°C. The hot microemulsion so formed was poured into ice-cold water previously 
164 maintained at 4°C and stirred continuously for 20 min at 3000 rpm to get the PNCs [15, 25-28] .
165 2.3. Systematic optimization and validation of PNCs 
166 TQ-loaded PNCs were optimized using three-level, Box–Behnken design (BBD). The selected 
167 dependent variables were the amount of solid lipid (X1), liquid lipid (X2), and Smix (X3), employed 
168 at three different levels of each variable, viz. low (-1), intermediate (0), and high (+1). Various 
169 PNC formulations (Table 1) prepared as per the design were investigated for the response variables 
170 viz. particle size, and percent entrapment efficiency (%EE). Optimization data analysis was 
171 performed after evaluating prepared PNCs for the response variables. The response surface 
172 analysis was studied employing  three dimensional (3D) response surface plots, and two-
173 dimensional (2D) contour plots, generated using Design Expert® ver.10.0.1 (MS Stat-Ease Inc., 
174 Minnepolis, MN) [24,28].
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175 Validation of methodology was done by selecting 17 PNCs formulation from the numerical 
176 optimisation technique based on desirability function. The validated formulations were evaluated, 
177 and the observed and predicted values were critically compared for the responses.
178 2.4. Particle size determination and zeta potential
179 The particle size of the prepared PNC’s was determined by dynamic light scattering (Zetasizer 
180 2000 HS, Malvern Instruments Limited, Malvern, UK), installed at Chemistry Department, Panjab 
181 University, India. Whereas, zeta potential was measured by Delsa Nano C (Beckman Coulter 
182 LS13320), installed at University Institute of Pharmaceutical Sciences (UIPS) India. The 
183 formulations (0.1mL) were diluted up to 100mL with distilled water and mixed well before 
184 analysis at room temperature. The measurements were made at a detection angle of 90°, and the 
185 measurement position within the cuvette was automatically determined by the software.  
186 Approximately 1 mL of the sample was placed in the cuvette and the intensity of fluctuation of the 
187 laser beam was recorded, correlated with the particle size of the dispersed phase [29].
188 2.5. Percent Entrapment efficiency (%EE)
189 The %EE of TQ-PNC was determined by measuring free TQ in the aqueous phase, which was 
190 separated using ultrafiltration centrifugation. Approximately 1mL of TQ-PNCs was centrifuged at 
191 3000 rpm for 20 min. and filtered using Filter Unit 100 kDa (Millipore Co., Boston, USA). The 
192 supernatant (0.1 mL) was dissolved in ethanol (1 mL), and analyzed using HPLC method. %EE of 





195 Wherein T is the total amount of drug detected in both the supernatant and sediment, and C is the 
196 amount of drug detected only in the supernatant
197 2.6 Diffraction scanning calorimetry (DSC)
198 The DSC pattern of pure TQ, freeze dried TQ-loaded PNC, sucrose, Capmul and stearic acid were 
199 recorded via.  NETZSCH leading Thermal Analysis (DSC 204, F1 Phoenix ASC) (Germany). The 
200 samples (drug, lipid and formulation) were scanned in an aluminium pan at heating rate of 10 
201 ◦C/min over the temperature range of 20–350 ◦C under an inert argon atmosphere at a flow rate of 
202 20 mL/min. to evaluate the stability and compatibility
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203 2.7. Electron Microscopy
204 Transmission electron microscopy was used to determine the morphology of optimized PNC with 
205 the help of transmission electron microscope (TEM) installed at Indian Institute of Technology 
206 (IIT), Mandi, H.P., India. The PNCs were negatively stained with 1% (w/w) aqueous solution of 
207 phosphotungstic acid, and dried on a microscopic carbon-coated grid, and viewed under the 
208 microscope at suitable magnifications.
209 Field emission-scanning electron microscopy (FE-SEM) of the lyophilized sample was also 
210 performed to see the morphology of TQ-loaded PNCs. Samples were located on carbon conductive 
211 tap and placed inside the vacuum chamber [30]. Moving electron from tungsten filament was made 
212 the incident to the sample and surface morphology of nanoconstructs was determined by using FE-
213 SEM (Hitachi s-4800), installed at SAIF, Panjab University, Chandigarh, India.
214 2.8. X-ray diffraction (XRD)
215 The XRD pattern of pure TQ, freeze dried TQ-loaded PNC, sucrose, Capmul and stearic acid were 
216 recorded via. X’Pert PRO diffractometer system (Panalytical, Netherlands) with a Copper Kα 
217 radiation (1.54060 A) [31]. The tube voltage and current were fixed at 45 kV and 40 mA 
218 respectively. Each samples was placed in an aluminum container and measured by a continuous 
219 scan between 5 and 40° in 2θ with a step size of 0.017 [2].
220 2.9. FTIR spectroscopy
221 Infrared spectroscopy was performed by Attenuated total reflection Fourier transform infrared 
222 spectrometer (ATR-FTIR) to determine interaction between excipients, and the active drug i.e., 
223 TQ.
224 2.10. In vitro drug release kinetics
225 In vitro drug release was performed via dialysis membrane method. The membrane was made into 
226 pouches by tying the thread on both the ends, and both pure TQ suspension and equivalent TQ-
227 loaded PNCs were placed into the bags separately. The dialysis bags were then placed in a beaker 
228 containing in 25 mL of release media kept in water bath shaker maintained at 37°C and run at 100 
229 strokes/min [32]. For first 2 h, release was carried out in 0.1N HCl (pH 1.2) followed by phosphate 
230 buffer (pH 6.8) up to 12 h along with 2.5% w/v of Tween 80. Aliquots of 2 mL were withdrawn 
231 at regular time intervals and replaced with an equal amount of diffusion medium to maintain the 
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232 sink conditions. Samples were then analyzed using HPLC at λmax of 254 nm after appropriate 
233 dilution(s).
234 To study the release mechanism of the drug from PNC, the in vitro release data was fitted into 
235 various mathematical models viz. zero order, first order, Higuchi model and Korsermeyer Peppas 
236 model [33]. The kinetic model was selected on the best fit with the highest value of regression 
237 coefficient (r2).
238 2.11. In vitro drug release kinetics in simulated gastric fluid (SGF) and simulated intestinal fluid 
239 (SIF)
240 In vitro drug release was performed via dialysis membrane method. The membrane was made into 
241 pouches by tying the thread on both the ends, and both pure TQ suspension and equivalent TQ-
242 loaded PNCs were placed into the bags separately. The dialysis bags were then placed in a beaker 
243 containing in 25 mL of release media kept in water bath shaker maintained at 37°C and run at 100 
244 strokes/min [32]. For first 2 h, release was carried out in  SGF (pH 1.2) followed by SIF (pH 6.8) 
245 up to 8 h along with 2.5% w/v of Tween 80. Aliquots of 1 mL were withdrawn at regular time 
246 intervals and replaced with an equal amount of fresh diffusion medium to maintain the sink 
247 conditions. Samples were then analyzed using HPLC at λmax of 254 nm after appropriate dilution(s) 
248 and the cumulative amount of drugs released was calculated.
249 2.12. Stability studies
250 The stability of the developed formulation was studied in simulated gastrointestinal (GI) fluids 
251 (SGF pH 1.2 and SIF pH 6.8). Briefly, 10ml of simulated GI fluids were added into 2 mL of PNC 
252 and incubated for 2 h in case of SGF (pH 1.2) and for 6 h in case of SIF (pH 6.8). Following the 
253 incubation, the formulation was evaluated for particle size, PDI and %EE.
254 2.13. Caco-2 cell culture studies
255 2.13.1. Qualitative Uptake study
256 For the qualitative cell uptake study the Caco-2 cells were employed at a density of 50,000 
257 cells/well in 6 well plate (Costars, corning Inc., NY, USA). The harvested cells were seeded and 
258 kept overnight for the attachment of cells. Afterward, the incubation of the cells was done with 
259 free Coumarin 6 (C-6) and C-6 loaded PNC (equivalent to 1 μg/mL of free C-6) for 3 h. The 
260 medium was removed after the incubation was finished. Further, Hank’s balanced salt solution 
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261 (HBSS) was used for washing the cells thrice followed by observing under the Confocal Laser 
262 Scanning Microscope (CLSM) (Olympus FV 1000) [34]. 
263 2.13.2 Quantitative uptake
264 The quantitative cell uptake study was performed as per the previous report [34]. Briefly, Caco-2 
265 cells were seeded at a density of 1x105 cells/well in six well cell culture plates (Costars, Corning 
266 Inc., NY USA). The medium of cell culture was replaced with fresh medium having a set 
267 concentration (10 μg/mL) of native TQ and PNC and further incubated for variable time intervals 
268 of 0.5 h to 3 h to evaluate the time dependent cell uptake. After, the period of incubation was 
269 accomplished the pre-existing medium was discarded followed by washing of cells thrice by 
270 HBSS. Further, the lysis of the cells was done with 0.1% Triton™ X-100 and methanol was 
271 employed for extraction in order to solubilize the drug, which was internalized. Finally, the 
272 centrifugation (Sigma K 300, USA) of cell lysates, which were obtained, was done at 34,000 rcf 
273 for a period of 10 min. The supernatant obtained was then quantified for TQ with the aid of 
274 validated HPLC method.
275 2.14. In vivo studies
276 2.14.1. Oral pharmacokinetics
277 The rats were randomly divided into two groups (n = 6). The first group was orally administered 
278 with TQ (20 mg/kg) dispersed in 4% sodium carboxymethylcellulose (CMC-Na) and for second 
279 group single dose of TQ-loaded PNCs (20 mg/kg) was administered. Blood samples of 0.5 mL 
280 each were withdrawn from the retro-orbital plexus under light anaesthesia at specified time 
281 intervals (pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, and 24 h), placed into heparinized eppendorff 
282 tubes and instantly centrifuged at 3000 rpm for 15 min. [2, 26]. After centrifugation, the plasma 
283 obtained was stored at −40 °C until further analysis. Extraction of TQ from rat plasma was 
284 performed and analyzed employing HPLC [35].
285 2.15. PCM-induced hepato-toxicity
286 The rats were randomly divided into 5 groups (n = 4) namely normal control group (Group I), 
287 which were provided a daily dose of 1 mL aqueous solution of 0.9 % w/v sodium chloride (NaCl) 
288 (p.o.) for 7 days. Toxic group (Group II) received (650 mg/kg) PCM once daily for 7 days to 
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289 induce hepatic damage. TQ-suspension (Group III) dispersed in 4% sodium 
290 carboxymethylcellulose (CMC-Na) (1mL) (20mg/kg) were administered orally, TQ-loaded PNC 
291 suspension group (Group IV) received (20mg/kg) daily dose for 7 days, and standard group treated 
292 with an oral suspension of Silymarin tablet (SILYBON®) (40 mg/kg) for 7 days (Group V) 
293 (40mg/kg). The rats in the toxic group (Group II) was given oral dose of 650 mg/kg (PCM) for 
294 seven days. All the groups, including toxic group (group II), except group I (control) received 
295 concurrent dose of 650 mg/kg PCM p.o for 7 days, while the rats in the normal control group was 
296 given the vehicle (normal saline) only. After 7 days, about 1 mL of the blood sample was 
297 withdrawn from the retro orbital plexus under light ether anaesthesia. The blood was collected in 
298 non-heparinized tubes, centrifuged at 1500 rpm for 15 min, the serum was separated and frozen at 
299 −80◦C until further testing. The serum so obtained was analyzed for various enzymes such as 
300 alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphate (ALP), 
301 bilirubin and albumin respectively [12,36-37].
302 2.16. Histopathological examination
303 Liver tissue samples were excised on the last day of the study. The samples were washed with 
304 phosphate buffer saline, dried with tissue paper and preserved in 10% formalin solution. These 
305 liver sections were stained with haematoxylin and eosin (H&E) and examined under a light 
306 microscope for the presence of any necrosis, haemorrhage, and inflammatory cells. 
307 Statistical analysis
308 The data obtained are reported as mean ±SD. Data statistical analysis was performed by Graph 
309 Pad Prism 8.0. The data from different formulations were compared for statistical significance by 
310 the one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison Test. A 
311 difference was considered statistically significant at the level of p < 0.05. 
312 3. Results 
313 3.1. Formulation and optimization PNC formulation
314 The maximum solubility of TQ was obtained in the stearic acid (solid lipid) and capmul (liquid 
315 lipid) (data not shown), thus selected for the development of PNCs. For the optimization of TQ-
316 loaded PNCs, a three-factor, three-level Box-Behnken design was employed [24]. Table 1 
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317 summarises an account of the 17 experimental runs studied, along with the coded values and actual 
318 values for the studied factors. The %EE, and particle size values obtained for the various PNC 
319 formulations are enumerated in table 1 and figure 1 (a-f)
320 The data analysis was carried out by analysing the response variables employing second-order 
321 quadratic polynomial models (p<0.0001) [28]. The r2 values for these models (particle size = 
322 0.9903; %EE = 0.9909) indicating excellent goodness of fit. The models was also found to have 
323 insignificant values of ‘‘lack of fit’’ endorsing the relevance of proposed model was appropriate. 
324 Closeness in the magnitude of adjusted and predicted r2 to the actual model r2 also supported an 
325 excellent good of fit t  the data.
326 3.1.1 Model Generation
327 The data analysis was carried out by analysing the response variables employing second-order 
328 quadratic polynomial models (p<0.0001) [26]. Application of ANOVA suggested that the chosen 
329 quadratic model was highly significant (p<0.05) along with the model terms (p<0.0001). The r2 
330 values for these models (particle size = 0.9903; %EE = 0.9909) indicating excellent goodness of 
331 fit. The models was also found to have insignificant values of ‘‘lack of fit’’ endorsing the relevance 
332 of proposed model was appropriate. Closeness in the magnitude of adjusted and predicted r2 to the 
333 actual model r2 also supported an excellent good of fit to the data. The special polynomial 
334 mathematical model encompassing ten coefficients (β0- β33) was postulated with β0 as the 
335 intercept. All the coefficients represent quadratic and interaction terms, as depicted in Eq. 2
336
337 Y=β0 + β1X1 + β2X2 + β3X3 + β12X1X2 + β13X1X3 + β23X2X3 + β11X12 + β22X22 + β33X32         (2) 
338   3.1.1.2 Model Optimization
339 Optimization was done based on desirability function in order to get the desired goal for the 
340 response variables. The optimum formulation was selected based on the criteria, i.e., minimum 
341 value of particle size and maximum value of %EE by applying constraints. The desirability 
342 function, ‘r’ near or equal to unity was assigned as an indicator of the best-fit composition with 
343 desired features. Table 2 presents various constraints and possible solutions with their numeric 
344 range of desirability.
345
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346 3.1.1.3 Model Validation
347 A total of 7 check-point formulations were chosen from the RSM, evaluated and the observed data 
348 compared with the predicted responses (Table 3). Linear correlation plots drawn between the 
349 actual and the predicted response variables demonstrated high values of r2. (particle size = 0.9879; 
350 %EE = 0.9552) indicating excellent goodness of fit. The overall bias for response variables found 
351 to be -0.044 ± 0.096%, indicating very high degree of predictive ability of the QbD experiments. 
352 The residual plots were found to be quite regulated, as they showed uniform, relatively narrow and 
353 random scatter around the zero-axis. 
354 3.2. Characterization of optimized PNCs
355 The optimized composition was selected as the solid lipid 1 gm, liquid lipid 0.69 gm and Smix (1:1) 
356 1gm, which were advocated to achieve the requirements of the optimized PNC formulation. 
357 Particle size of the optimized PNC was less than 100nm (i.e. 83.5nm and %EE of the optimized 
358 PNC was found to be 94.4%.
359 The particle size distribution (PDI) was found to be 0.55, which is in acceptable range [38], as 
360 shown in Figure 2(a). The zeta potential valu  was obtained to be −0.64. 
361 DSC analysis revealed the melting point of TQ, stearic acid, capmul and PNC. DSC thermogram 
362 of TQ showed sharp endothermic peak around 47 °C, which corresponds to its melting point range, 
363 as mentioned in the literature (45-50 ◦C). Whereas, stearic acid, capmul and PNC exhibits a sharp 
364 endothermal peak at 60 °C, 150 °C and 165 °C respectively as shown in figure 2 (b).  Whereas 
365 (figure 2(c) and (d) shows the TEM and FE-SEM photomicrographs of the developed nanocarrier 
366 system, respectively. The TEM images of optimized PNCs reveal that the particles were spherical 
367 in shape, in agreement with the size obtained using DLS i.e. below 100 nm. The SEM images also 
368 displayed nearly spherical topography of prepared PNC’s. No crystalline drug particles were 
369 visible as shown in Figure 2(c,d). The XRD pattern of pure TQ, TQ-PNC, sucrose, Capmul and 
370 stearic acid is displayed in Figure 2(e). The XRD pattern of the pure TQ demonstrates high 
371 intensely peak, showing its crystalline nature, while stearic acid and Capmul exhibited 
372 comparatively low intensity peaks indicating their amorphous nature. TQ-PNCs demonstrated a 
373 marked decrease in the intensity of TQ peak. 
374 For the estimation of any possible chemical interaction among TQ and excipient, FTIR spectra of 
375 TQ, Physical mixture, sucrose and stearic acid, Overlay spectra, of drug, the excipients, and 
Page 13 of 53





























































For Peer Review Only
14
376 physical mixture is represented in Figure 2(f), while their interpretations, are included in the Table 
377 4. The FTIR spectrum of the pure TQ showed the sharp peak at 2970 cm−1  corresponds to (free 
378 CH stretching, 2800-3200 cm−1), the peak present at 1644 cm−1 corresponds to (C=O and C=C 
379 stretch,1670-1820 cm−1), the peak present at 1360 corresponds to  (-CH bending, 1350-1480 cm−1). 
380 The FTIR spectrum of stearic acid exhibited peaks at 3492 cm−1 corresponds to (-OH stretch, 3200-
381 3600 cm−1), the peak presented at 2920 cm−1 corresponds to (-CH stretch, 2850-3000 and  peak at 
382 1707 corresponds to (C=O stretch and C=C stretch, 1670-1820 cm−1).  The FTIR spectrum of 
383 sucrose exhibited a sharp peak at 2927 cm−1 corresponds to (-CH stretch, 2850-3000 cm−1). The 
384 peak presented at 3667 cm−1 corresponds to (-OH stretch, 3500-3700) peak appeared at 1395 cm−1  
385 corresponds to (-CH stretch, 1350-1480).  There was a shifting of the peak of TQ benzene ring and 
386 carbonyl, group (C=C, C=O) from 1644cm −1 to and 1771 cm−1 in the physical mixture.
387 3.3. In vitro release kinetic
388 The release profile of TQ from plain TQ suspension and optimized PNC formulation is shown in 
389 Figure 2(g). It is vivid from the results, that there was much better release of the drug from PNCs 
390 vis-à-vis plain TQ suspension. Approximately 80% of the drug was released from TQ-PNCs up to 
391 12h, whereas, only 50% of TQ was released from pure TQ suspension. In initial 2 h, approximately 
392 31.5% of the drug was released from PNC vis-à-vis pure TQ (10.8%) followed by sustained release 
393 at a constant rate. 
394 After fitting the release data into various kinetic models, the best-fit model was found to be Higuchi 
395 model, which indicated the controlled release behavior of the drug from PNC matrix. 
396 3.5. In vitro drug release (SGF) and (SIF)
397 The release profile of TQ from plain TQ suspension and optimized PNC formulation is shown in 
398 Figure 2(h). Almost 100% of the pure TQ drug release was achieved within 1 h, which indicated 
399 the rapid diffusion of TQ. The initial burst release was seen in the first 30 min. and nearly 40% of 
400 the total amount of TQ was released, followed by a sustained release of the remaining TQ over 
401 nearly 8 h (91.74%) [Figure 2(h)]. 
402 3.6 Stability of PNC in simulated GI fluids
403 As PNC was designed for oral administration, therefore the main goal behind stability study in 
404 simulated GI fluid is to first protect the drug from degradation while passing through harsh 
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405 environment in GI tract. PNC were able to maintain their integrity upon incubation with simulated 
406 GI fluids for specified time. The results showed the insignificant changes in all the formulation 
407 parameters viz. particle size, PDI and %EE (Table 5). 
408 3.7 Qualitative and quantitative cell uptake
409 The uptake of PNC were assessed in Caco-2 cells to predict the possibility of GI membrane 
410 associated transport. CLSM images of PNC exhibited higher fluorescence vis-à-vis pure TQ. 
411 Figure. 2(i) (I) and (II) depicts CLSM images of pure TQ and respectively. Similarly, quantitative 
412 uptake of PNC and pure TQ in Caco-2 cells was performed to further validate the outcomes of 
413 CLSM analysis. The time dependent cell uptake of pure TQ and PNC by Caco-2 cells is depicted 
414 in Fig. 2(j). The study showed significantly higher uptake (p < 0.05) of PNC vis-a-vis pure TQ. In 
415 addition, the cellular uptake was improved when there was an increase in the incubation time from 
416 0.5 to 3h. After 3 h of interval, the % cell uptake was 7.2 % and 41.2 % for pure TQ and PNC 
417 respectively at concentration 10 μg/mL.
418 3.6. Oral pharmacokinetics 
419 The plasma concentration-time profile graph of optimized PNC formulation exhibited better 
420 enhancement in in vivo absorption of TQ vis-à-vis TQ suspension as shown in figure 3 (A). Various 
421 pharmacokinetic parameter for TQ-PNC and TQ suspension is entailed in Table 6. The tmax value 
422 was detected to be 4.9 h for TQ-PNC and 4.1 h for pure TQ suspension. Whereas, t1/2 was found 
423 to be 2.3 h for TQ-PNC and 1.9 h for pure TQ suspension. Cmax value was found to be 136.53±1.38 
424 μg/mL for TQ-PNC and 43.83±1.09 μg/mL for pure TQ suspension. While, AUC(0-t) and AUC(0-
425 ∞) of TQ-PNC were found to be 948.60±4.37 and 1882.26±6.71 μg.h/mL, respectively, which were 
426 highly significant (P<0.05) in comparison with AUC(0-t) (245.73±1.68 μg.h/mL) and AUC(0-∞) 
427 (253.31±5.91 μg.h/mL) of pure TQ suspension. TQ-PNC showed relative bioavailability of 
428 386.03% based on mean AUC(0–∞) compared to TQ-suspension, indicating the improved 
429 bioavailability of the drug in the phospholipidic nanoconstructs. 
430 3.5. Hepatoprotective activity 
431 3.5.1. Serum biochemical estimation
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432 In vivo hepato-protective effect of TQ-PNCs was studied against PCM-induced hepatotoxicity. 
433 PCM administration produced a significant hepatotoxicity. Result of biochemical parameters 
434 (ALT, AST, ALP, albumin and total bilirubin) for various groups are given in Table 7 and Figure 
435 3 (B). Severe liver damage in the toxic group can be seen by significant increase in the marker 
436 enzymes. Compared to the control group and treatment groups (pure TQ, PNC and silymarin 
437 group), PCM administration induced significant increase in ALP, ALT, AST, bilirubin and 
438 albumin level production (p <0.001). Treatment for seven days caused the reduction in the ALP, 
439 ALT, AST, bilirubin and albumin levels in all the treated groups. Plain TQ suspension revealed 
440 almost same levels of biomarker enzymes vis-a-vis standard treatment however, encapsulation of 
441 TQ in the PNC significantly reduced the liver biomarker enzymes. 
442 3.6. Histopathological evaluation 
443 The results of histopathology of normal, toxic control, TQ suspension, optimized PNC and 
444 Silymarin group are presented in Figure 3 (C). Normal group animals showed normal liver with 
445 no signs of inflammatory cells and necrosis and showed the usual lobular building. While the 
446 sections of toxic group showed notable changes viz. parenchymal cell injury, lymphocytes and 
447 macrophages infiltration including necrosis and degeneration. However, the animals treated with 
448 TQ suspension presented no sign of inflammation and necrosis with minor lymphocytic 
449 infiltration. While TQ-PNC treated, animals showed normal lobular architecture in a more distinct 
450 manner as compared to TQ suspension, and similar to normal group with few lymphocytes and 
451 normal vacuoles. The standard treatment group, i.e., Silymarin, showed almost normal appearance 
452 of liver parenchyma, however with few scattered foci with no signs of inflammation and necrosis 
453 in hepatocytes.
454 4. Discussion
455 In the recent past, there has been a tremendous resurgence of research on the bioactive components 
456 isolated from the plants, for their prophylactic and therapeutic worth. The strong antioxidant and 
457 anti-inflammatory effects, has made TQ a convincing candidate for the treatment of 
458 hepatoprotective disorders, as evidenced from the previous literature. However, like other plant- 
459 based molecules the delivery of TQ via oral route is difficult, owing to its poor biopharmaceutical 
460 properties. The aim of this paper was to encapsulate TQ inside the phospholipidic nanoconstructs, 
461 which can protect the drug, enhance the bioavailability, and target the drug to the liver and thereby, 
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462 releasing the drug in a controlled manner. For the development of PNCs, determination of 
463 solubility of the drug in solid lipids, and liquid lipid is a critical aspect. The solubility of the drug 
464 in lipids is the most significant, as the ability of the PNCs to maintain the drug in solubilized form 
465 is largely influenced by the solubility of drug in the lipidic core of the nanoconstructs. To construct 
466 the PNCs, phospholipid was employed as the surfactant. However, it is reported that phospholipids 
467 are able to increase the crystallization temperature (Tc) of triglycerides by acting as a template for 
468 surface heterogenous nucleation. Phospholipid molecules bound to vesicles, exhibit only a limited 
469 mobility and thus, fail to immediately cover the newly created interfaces during recrystallization. 
470 Due to the low mobility of the phospholipid molecules, sudden lack of emulsifier on the surface 
471 of the particle leads to particle aggregation and increase in the particle size of lipidic 
472 nanoconstructs [39]. Thus, the blend of nonionic surfactants are required to regulate and balance 
473 the crystallization, which can further stabilize the particle size of nanoconstructs [40].
474 TQ-loaded PNC formulations were optimized employing BBD to get the best optimal composition, 
475 and investigated for %EE, and particle size as the response variables. In the current studies, all the 
476 input variables, i.e., the amount of solid lipid, liquid lipid and Smix had a significant impact on the 
477 particle size. A nonlinear dip in the values of particle size followed by a rising trend was observed 
478 with increase in the liquid lipid and solid lipid concentration (Figure 1a). Similarly, a twisted 
479 shaped graph is obtained in the case of Smix and solid lipid, as there was a non–linear increase in 
480 particle size with increase in Smix. Firstly, there was a decreasing trend in particle size up to the 
481 mid-level of Smix, followed by a slight increase in the particle size. Whereas, in the case of solid 
482 lipid there was a sharp initial decline in the particle size followed by a rising trend (Figure 1b). 
483 Furthermore, (Figure 1c) depicted that with increase in Smix and liquid lipid concentration, the 
484 particle size tended to decrease first, followed by a non-linear increase in both the cases. With the 
485 increase in lipid concentration, an increase in particle size can be due to decrease in emulsifying 
486 efficiency of surfactant and thus, increase in particle agglomeration. Figure 1(d-f) depicts the 2D-
487 contour plots and 3D-response surface plots for %EE. However, all the input variables had a 
488 positive influence on the % EE of the drug, yet Smix had a more pronounced effect. Both liquid 
489 lipid and solid lipid at all the levels positively influenced the %EE of the drug. With increase in 
490 the liquid lipids concentration, there was an upsurge in the %EE of drug up to a certain level and 
491 then it became constant. While in the case of solid lipid a non-linear increase in the %EE was 
492 observed (figure 1d). However, it can be seen from the figure 1(e, f) that with increase in the Smix, 
Page 17 of 53





























































For Peer Review Only
18
493 there was sharp rise in the %EE of the drug vis-à-vis solid lipid and liquid lipid. This is attributed 
494 to the fact that high lipid and Smix concentration allows the better stabilization and solubilization 
495 of drug in the lipid blend, thus led to the enhancement of %EE. 
496 Optimized TQ-PNC formulation showed smallest particle size (83.5nm) which was possibly due 
497 to the presence of optimal combination of PL90G and T80 (1:1) as Smix at appropriate 
498 concentrations. The presence of nonionic surfactants and their blends with phospholipids often led 
499 to the particle stabilization.
500 The (PDI) (i.e. 0.55) demonstrating the good uniformity of particle size distribution. The zeta 
501 potential value was close to zero (−0.64), which is due to the presence of a non-ionic surfactant 
502 T80, responsible to stabilize systems by creating spatial inclusion [41,42]. The %EE of the 
503 optimized PNC was found to be 94% revealing that the microemulsification method with the apt 
504 optimization of solid lipid, liquid lipid and Smix (T80:PL90G) can yield such high value of %EE. 
505 Further, it has been observed that high phospholipid content reduces the risk of drug loss to the 
506 external phase, and thus provide more space to incorporate the drug, resulting in improved 
507 entrapment efficiency. This may also be due to an excess of phospholipid possibly forming 
508 multilayers around the particle.
509 The DSC thermogram of PNC does not show any peak pertaining to thymoquinone, which reveals 
510 the complete entrapment of TQ in the lipidic nanocarriers. The surface morphology of optimized 
511 PNCs reveal that the particles were spherical in shape, in agreement with the size i.e. below 100 
512 nm. Moreover, no crystalline drug particles were visible. The XRD pattern of the pure TQ 
513 demonstrates high intensely peak, showing its crystalline nature compared to TQ-PNCs. A marked 
514 decrease in the intensity of TQ peak in TQ-PNC, indicating the solubility and stability of the drug 
515 in the PNC core. In FT-IR study, all the peaks relating to functional groups (hydroxyl, methyl, 
516 carbonyl) of all the excipients are intense and clear in the FTIR spectrum of the physical mixture. 
517 Thus, it can be inferred that there was no interaction between the drugs and the excipients, 
518 employed in various nanocarrier formulations. Also, the drug was stable and compatible with the 
519 excipients.
520 TQ-PNC showed significantly high drug release compared to pure TQ.  It was observed that 
521 approximately 30% of the drug was released from PNC in first 2 hours vis-à-vis TQ followed by 
522 sustained release at a constant rate. This might be due to the presence of lipidic core and can be 
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523 explained in three aspects, i.e., the presence of drug at the surface of PNCs, secondly liquid lipid 
524 and thirdly, smaller particle size [43]. In first case, TQ might be adsorbed at the surface of the 
525 nanoconstructs due to the presence of Smix, secondly liquid lipid was distributed in solid lipid core, 
526 which leads to the formation of imperfect crystalline structure of PNC and thus increasing the rate 
527 of drug release [44]. In third case, smaller particle size in case of optimized PNC formulation offers 
528 the greater surface area, and hence, improves the contact between particles and dissolution 
529 medium. The best-fit model for PNCs was found to be Higuchi model indicating the controlled 
530 release mechanism of drug release from the nanoconstructs. This could be ascribed to the lipophilic 
531 nature of TQ, which is entrapped deeply in the lipidic core matrix in the solubilized form and 
532 thereby, slow diffusion of drug molecules via the phospholipid matrix of PNCs. The release profile 
533 of TQ from plain TQ suspension and optimized PNC formulation from GI fluids is shown in Figure 
534 2(h). The initial burst of TQ release from the PNC may be due to the presence of TQ molecules on 
535 the surface closest to PNC molecule. The sustained release phase may be associated to the diffusion 
536 of TQ molecules from the lipid core, which leads to the immobilization of drug from the PNC 
537 molecule. In addition, it may be because of the effect of decreasing TQ amount [45].
538 A stability test in simulated GI tract was designed to investigate the effect of composition on 
539 stability of nanocarriers. As said earlier the main aim behind stability study in simulated GI fluids 
540 was to first protect the drug from degradation from the harsh GI tract environment until it reaches 
541 the intestine. After reaching in the intestine, drug will be digested by intestinal enzyme to form 
542 mixed micelles composed of lipid degradation products (fatty acids, monoglycerides etc.), bile 
543 salts and phospholipids entrapping drug thus enhancing its bioavailability. The results showed the 
544 insignificant changes in all the formulation parameters viz. particle size, PDI and %EE (Table 5). 
545 Although, PNC was found to be more stable in SGF compared to SIF. This stability of PNC in 
546 acidic pH might be due to presence of nonionic surfactants i.e., T80, which leads to the steric 
547 stabilization effect. These nonionic surfactants are unresponsive to flocculation and coalescence 
548 in low pH due to their molecular structure. Whereas in case of SIF particle aggregation can occur 
549 sometimes due to the  release of surfactant layer from the surface of lipidic nanocarriers by lipase, 
550 thus leading to nanocarrier aggregation and exposing the surface of nanocarriers for lipid 
551 hydrolysis by intestinal enzymes [46].
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552 The cellular uptake of PNC were assessed in Caco-2 cells [(Figure 2(i) (I-II) and 2(j)]. The particle 
553 size of PNC was found to play important role in the efficient uptake through GIT. The size of PNC 
554 was found to be less than 100 nm. This confirmed the effective intestinal uptake, mostly in the 
555 lymphoid region, which helped in bypassing the first pass metabolism. In addition, the large 
556 surface area by nanosized PNC enhances the contact between the drug and the cell membrane, 
557 thereby augmenting the cell uptake of drug. Furthermore, the combined mechanism between lipids 
558 and surfactants can improve drug absorption by enhancing affinity for cell membranes with 
559 lipophilicity. Therefore, these results supported that TQ could be taken up into Caco-2 cells by 
560 amalgamation into PNC [47].
561 In in vivo animal pharmacokinetics, TQ-PNC showed 3.8-fold enhancement in the relative 
562 bioavailability vis-à-vis TQ-suspension, indicating the improved bioavailability of the drug in the 
563 lipid-based nanoparticles formulation. The improved pharmacokinetic and oral bioavailability of 
564 the TQ from lipidic matrix was probably because of combined promotion mechanisms. Firstly, the 
565 ability to adhere to gut wall. The ultrafine dispersions within nanometer range imparts them with 
566 a tremendous specific surface area and thus the possession of adhesion to gut wall, which is helpful 
567 to oral absorption. Secondly, the nano-sized formulation and the presence of Smix as suitable 
568 solubilizers of TQ in lipidic core. Furthermore, faster absorption of TQ incorporated into lipidic 
569 matrix helped in avoiding first pass extensive gut wall metabolism due to close association of drug 
570 with lipid vis-a-vis plain TQ. Thirdly, being a lipid-based system, PNCs may promote the uptake 
571 by M-cells in the Payer’s patches and increase the absorption through the lymphatic pathway [48]. 
572 The observations from biochemical parameters showed that compared to the control group and all 
573 the groups including TQ-PNC showed significant decrease in ALP, ALT, AST, bilirubin and 
574 albumin level production (p <0.001) after PCM administration. Whereas reduction in the 
575 biomarker enzyme was more pronounced in the TQ-PNC group compared to all other groups (p 
576 <0.001). The effect may be assigned to the higher cellular permeability of TQ achieved by PNCs. 
577 PNCs with the blend of T80 and PL90G as a surfactant and co-surfactant, respectively, are 
578 anticipated to interact with the membrane lipids of liver cells resulting in physiologically 
579 significant effects as shown in this study [49] . Moreover, other hypothesis can be ascribed that 
580 the passage across endothelial fenestrations of carriers smaller than 100 nm can effectively target 
581 hepatic stellate cells HSCs (in rats). In addition, the presence of lipidic carrier facilitates capture 
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582 by the liver and other organs. Overall, these results specified that optimized TQ-PNC showed 
583 enhanced hepatoprotective effects against PCM-induced liver damage. The results of biochemical 
584 examinations were further supported by the histopathological investigations in rats liver samples.
585 5. Conclusion 
586 The present research work, have successfully prepared TQ-loaded PNCs and systemically 
587 optimized employing BBD, which helped in providing the optimal composition of three 
588 independent variables to select the best-optimized formulation. The prepared nanoconstructs 
589 demonstrated initial burst release followed by controlled release. Pharmacokinetic studies proved 
590 the potential of nanolipidic carriers to alleviate the challenge of lower bioavailability of TQ. 
591 Pharmacological effects of selected optimized PNC formulations showed significant reduction of 
592 various liver biomarkers compared to toxic group, which was further substantiated by 
593 histopathological examination of liver sections. Hence, we expect that these investigations can 
594 provide a new strategy for the development of nano-medicine and suggest TQ as a strong candidate 
595 for a new generation of hepato-protective molecule with reduced side effects in the not so distant 
596 future. The outcomes of the studies can be xtrapolated to variety of bioactives and drugs with 
597 similar challenges and hurdles.  
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796
797 Figure 1. Two-dimensional contour plots and corresponding three-dimensional response surface 
798 plot depicting the effect of various input variables on; (a) Particle size; Liquid lipid(X2), solid lipid 
799 (X1); (b) Smix (X3), solid lipid (X1); (c) Smix (X3), Liquid lipid (X2) and effect of various input 
800 variables on %EE (d) Liquid lipid(X2), solid lipid (X1); (e) Smix (X3), solid lipid (X1); (f) Smix (X3), 
801 Liquid lipid (X2).
802 Figure 2. (a) Particle size distribution of optimized PNC formulation, (b) DSC graphs of drug, 
803 PNC, capmul and stearic acid, (c) TEM microphotograph (at 60,000X) of TQ-loaded PNCs (d) 
804 FE-SEM microphotograph (at 30,000X) of TQ-loaded PNCs, (e) XRD spectra of pure drug, PNC, 
805 sucrose, capmul and stearic acid .(f) Overlay FTIR spectrum of drug and the excipients A: TQ, B: 
806 Physical mixture, C: Sucrose, D: Stearic acid, (g) Comparative in vitro release of optimized TQ-
807 PNC and pure TQ, (h) Comparative in vitro release of optimized TQ-PNC and pure TQ in SGF 
808 and SIF, (i) Qualitative cell uptake of C-6 loaded PNC (I) Free C-6 and (II) C-6 loaded PNC, 
809 where (a) images under green fluorescence channel of C-6 pannel (b) corresponding differential 
810 interface contrast image of the cell (c) superimposition of the panel (a and b), Panel (d) and (e) in 
811 all the images shows vertical and horizontal line series of fluorescence along with the yellow line 
812 of the image (c) respectively. (j) The time dependent cell uptake of pure TQ and PNC by Caco-2 
813 cells 
814 Figure 3(A). Plasma concentration-time profile curve of TQ after oral administration of optimized 
815 PNC and TQ suspension (mean±SD, n=6) (B) Effect of various formulations on serum and tissue 
816 biochemical parameters. Data is presented as Mean ± SD (n = 4) and analyses by one-way analysis 
817 of variance followed by Tukey's Multiple Comparison Test. aP < 0.001 vs saline control, bP < 
818 0.001 vs toxic group and cP < 0.05 vs standard. (C) a) Normal control showed normal sinusoidal 
819 architecture and no fibrosis; b) Toxic  group showed Parenchymal cell injury with lymphocytes 
820 and macrophages infiltration, along with inflammation and apoptosis; c) TQ suspension group 
821 showed mild lymphocytic portal infiltrate; d) TQ-PNC showed few lymphocytes and normal 
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935 Figure 2 (a-j)
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964 Figure 3 (B)
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969 Table 1
970 Experimental runs of BBD design matrix and their responses
971 Table 2 
972 Constraints for numeric optimization and predicted solutions
973 Table 3 
974 Comparison of experimental results with predicted responses
975 Table 4
976 Drug-excipient interaction employing FT-IR
977 Table 5
978 Stability of PNC in simulated GI fluids
979 Table 6
980 Pharmacokinetic parameters (mean±SD) after oral administration of TQ –PNC and TQ suspension 
981 in rats (n=6)
982 Table 7
983 Effects of optimized TQ-PNC and TQ treatments on Serum and Tissue Biochemical Parameters 
984 (mean±SD, n=4) 
985 Table 1
Runs Solid Lipid Liquid lipid *Smix 
(T80:PL90G) 
%EE Particle size (nm)
1 0 0 0 99.2 88.9
2 1 1 0 97.5 89.3
3 0 1 1 83.78 91.5
4 -1 0 1 98.4 89.6
5 0 0 0 99.2 87.3
6 1 -1 0 112.8 75.5
7 0 1 -1 110.2 69.9
8 0 0 0 100.6 85.5
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9 1 0 -1 109.2 72.5
10 0 -1 1 106.1 78.3
11 -1 0 -1 109.6 63.5
12 0 -1 -1 109.3 63.3
13 -1 -1 0 113.6 75.3
14 1 0 1 90.5 87.3
15 0 0 0 99.9 86.9
16 0 0 0 96.5 85.5
17 -1 1 0 105.3 84.9
Level used, actual (coded)Independent variables (g)
Low(-1) Medium (0) High(+1)
Solid Lipid 1 3 5
Liquid Lipid 1 3 5
Smix 1 3 5
986 *T80:PL90G was fixed in the ratio of 1:1 
987
988 Table 2
Variable Goal Lower limit Upper limit Importance
A:Solid lipid maximize -1 1 ***
B:Liquid lipid is in range -1 1 ***
C:Smix maximize -1 1 ***
Particle size minimize 83.78 113.6 ***
%EE is in range 63.3 91.5 ***
A B C Particle size %EE Desirability
1 0.69 1 83.44 90.17 1.000 Selected
1 0.85 1 82.37 90.48 1.000
1 0.83 1 82.52 90.45 1.000
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1 0.938 1 81.93 90.55 1.000
1 0.668 1 83.61 90.11 1.000
1 0.993 1 81.66 90.57 1.000










Particle size (nm) 83.44 83.47 -0.04
OPT
%EE 90.18 90.12 0.07
Particle size (nm) 82.37 82.39 -0.02
VAL-1
%EE 90.48 90.39 0.10
Particle size (nm) 82.52 82.42 0.10
VAL-2
%EE 90.45 90.51 -0.07
Particle size (nm) 82.06 82.12 -0.10
VAL-3
%EE 91.00 90.90 0.11
Particle size (nm) 82.76 82.70 0.06
VAL-4
%EE 91.00 90.81 0.21
Particle size (nm) 81.93 82.00 -0.07
VAL-5
%EE 90.54 90.50 0.04
Particle size (nm) 83.61 83.5 0.11
VAL-6
%EE 90.19 90.10 0.10
991
992 Table 4
Reported Peaks (cm-1) Observed Peaks (cm-1) Assignment
TQ
1670-1820 1644, 1614 -C=O stretch
2850-3000 2970,2925,2877              -CH stretch
1350-1480 1360 -CH bending
Physical Mixture
2850-3000 2929, 2853 -CH stretch
1670-1820 1741 C=O stretch
1900-2000 1920,1950 C=C stretch
3200-3600 3327,3387 -OH stretch
1350-1480 1350,1376 -CH stretch
Sucrose
2850-3000 2987 -CH stretch
3500-3700 3665 -OH stretch
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1350-1480 1395 -CH stretch
Stearic acid
3200-3600 3493 -OH stretch
2850-3000 2920 -CH stretch
1670-1820 1707 -C=O stretch
993
994 Table 5
Particle size (nm) PDI %EEFluids














Parameters TQ suspension TQ-PNC
Cmax (µg/mL) 43.83±1.09 136.53±1.38
t1/2 (h) 1.9 2.3
tmax (h) 4.1 4.9
Vd (L) 0.126 0.091
AUC(0-24) (µg.h/mL) 245.73±2.73 948.60
AUC(0-inf) (µg.h/mL) 253.31±1.98 1882.26
Relative bioavailability (F) 
(Ratio of AUC(0-t) of TQ-PNC 




Groups ALT (U/L) ALP (U/L) AST (U/L) Bilirubin 
(mg/dl)
Albumin
Saline control 35.9±10.46 104.41±2.54 59.2±3.21 0.40±0.01 5.1±0.06
Toxic control (PCM) 87.0±6.49 386.1±5.54 102.73±5.65 2.39±0.01 3.2±0.08
TQ suspension 47.41±7.64 168.20±2.01 79.86±4.65 0.60±0.02 4.8±0.21
TQ-PNC 39.2±9.23 110±1.67 69.7±2.55 0.58±0.03 4.5±0.04
Silymarin 45.3±6.01 121.31±1.62 73.90±3.54 0.50±0.01 4.3±0.10
998 Values were the means of three replicate samples. The data were presented as mean ± SD (n=4), ap<0.001 vs saline control, 
999 bp<0.001 vs toxic control and cp<0.05 vs Silymarin
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Figure 1. Two-dimensional contour plots and corresponding three-dimensional response surface 
plot depicting the effect of various input variables on; (a) Particle size; Liquid lipid(X2), solid lipid 
(X1); (b) Smix (X3), solid lipid (X1); (c) Smix (X3), Liquid lipid (X2) and effect of various input 
variables on %EE (d) Liquid lipid(X2), solid lipid (X1); (e) Smix (X3), solid lipid (X1); (f) Smix (X3), 
Liquid lipid (X2).
Figure 2. (a) Particle size distribution of optimized PNC formulation, (b) DSC graphs of drug, 
PNC, capmul and stearic acid, (c) TEM microphotograph (at 60,000X) of TQ-loaded PNCs (d) 
FE-SEM microphotograph (at 30,000X) of TQ-loaded PNCs, (e) XRD spectra of pure drug, PNC, 
sucrose, capmul and stearic acid .(f) Overlay FTIR spectrum of drug and the excipients A: TQ, B: 
Physical mixture, C: Sucrose, D: Stearic acid, (g) Comparative in vitro release of optimized TQ-
PNC and pure TQ, (h) Comparative in vitro release of optimized TQ-PNC and pure TQ in SGF 
and SIF, (i) Qualitative cell uptake of C-6 loaded PNC (I) Free C-6 and (II) C-6 loaded PNC, 
where (a) images under green fluorescence channel of C-6 pannel (b) corresponding differential 
interface contrast image of the cell (c) superimposition of the panel (a and b), Panel (d) and (e) in 
all the images shows vertical and horizontal line series of fluorescence along with the yellow line 
of the image (c) respectively. (j) The time dependent cell uptake of pure TQ and PNC by Caco-2 
cells 
Figure 3(A). Plasma concentration-time profile curve of TQ after oral administration of optimized 
PNC and TQ suspension (mean±SD, n=6) (B) Effect of various formulations on serum and tissue 
biochemical parameters. Data is presented as Mean ± SD (n = 4) and analyses by one-way analysis 
of variance followed by Tukey's Multiple Comparison Test. aP < 0.001 vs saline control, bP < 
0.001 vs toxic group and cP < 0.05 vs standard. (C) a) Normal control showed normal sinusoidal 
architecture and no fibrosis; b) Toxic  group showed Parenchymal cell injury with lymphocytes 
and macrophages infiltration, along with inflammation and apoptosis; c) TQ suspension group 
showed mild lymphocytic portal infiltrate; d) TQ-PNC showed few lymphocytes and normal 
vacuoles are present in the cells and e) Silymarin group showed normal hepatocytes cell and few 
scattered foci
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1 Table 1
2 Experimental runs of BBD design matrix and their responses
3 Table 2 
4 Constraints for numeric optimization and predicted solutions
5 Table 3 
6 Comparison of experimental results with predicted responses
7 Table 4
8 Drug-excipient interaction employing FT-IR
9 Table 5
10 Stability of PNC in simulated GI fluids
11 Table 6
12 Pharmacokinetic parameters (mean±SD) after oral administration of TQ –PNC and TQ suspension 
13 in rats (n=6)
14 Table 7
15 Effects of optimized TQ-PNC and TQ treatments on Serum and Tissue Biochemical Parameters 
16 (mean±SD, n=4) 
17 Table 1
Runs Solid Lipid Liquid lipid *Smix 
(T80:PL90G) 
%EE Particle size (nm)
1 0 0 0 99.2 88.9
2 1 1 0 97.5 89.3
3 0 1 1 83.78 91.5
4 -1 0 1 98.4 89.6
5 0 0 0 99.2 87.3
6 1 -1 0 112.8 75.5
7 0 1 -1 110.2 69.9
8 0 0 0 100.6 85.5
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9 1 0 -1 109.2 72.5
10 0 -1 1 106.1 78.3
11 -1 0 -1 109.6 63.5
12 0 -1 -1 109.3 63.3
13 -1 -1 0 113.6 75.3
14 1 0 1 90.5 87.3
15 0 0 0 99.9 86.9
16 0 0 0 96.5 85.5
17 -1 1 0 105.3 84.9
Level used, actual (coded)Independent variables (g)
Low(-1) Medium (0) High(+1)
Solid Lipid 1 3 5
Liquid Lipid 1 3 5
Smix 1 3 5
18 *T80:PL90G was fixed in the ratio of 1:1 
19
20 Table 2
Variable Goal Lower limit Upper limit Importance
A:Solid lipid maximize -1 1 ***
B:Liquid lipid is in range -1 1 ***
C:Smix maximize -1 1 ***
Particle size minimize 83.78 113.6 ***
%EE is in range 63.3 91.5 ***
A B C Particle size %EE Desirability
1 0.69 1 83.44 90.17 1.000 Selected
1 0.85 1 82.37 90.48 1.000
1 0.83 1 82.52 90.45 1.000
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1 0.938 1 81.93 90.55 1.000
1 0.668 1 83.61 90.11 1.000
1 0.993 1 81.66 90.57 1.000










Particle size (nm) 83.44 83.47 -0.04
OPT
%EE 90.18 90.12 0.07
Particle size (nm) 82.37 82.39 -0.02
VAL-1
%EE 90.48 90.39 0.10
Particle size (nm) 82.52 82.42 0.10
VAL-2
%EE 90.45 90.51 -0.07
Particle size (nm) 82.06 82.12 -0.10
VAL-3
%EE 91.00 90.90 0.11
Particle size (nm) 82.76 82.70 0.06
VAL-4
%EE 91.00 90.81 0.21
Particle size (nm) 81.93 82.00 -0.07
VAL-5
%EE 90.54 90.50 0.04
Particle size (nm) 83.61 83.5 0.11
VAL-6
%EE 90.19 90.10 0.10
23
24 Table 4
Reported Peaks (cm-1) Observed Peaks (cm-1) Assignment
TQ
1670-1820 1644, 1614 -C=O stretch
2850-3000 2970,2925,2877              -CH stretch
1350-1480 1360 -CH bending
Physical Mixture
2850-3000 2929, 2853 -CH stretch
1670-1820 1741 C=O stretch
1900-2000 1920,1950 C=C stretch
3200-3600 3327,3387 -OH stretch
1350-1480 1350,1376 -CH stretch
Sucrose
2850-3000 2987 -CH stretch
3500-3700 3665 -OH stretch
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1350-1480 1395 -CH stretch
Stearic acid
3200-3600 3493 -OH stretch
2850-3000 2920 -CH stretch
1670-1820 1707 -C=O stretch
25
26 Table 5
Particle size (nm) PDI %EEFluids














Parameters TQ suspension TQ-PNC
Cmax (µg/mL) 43.83±1.09 136.53±1.38
t1/2 (h) 1.9 2.3
tmax (h) 4.1 4.9
Vd (L) 0.126 0.091
AUC(0-24) (µg.h/mL) 245.73±2.73 948.60
AUC(0-inf) (µg.h/mL) 253.31±1.98 1882.26
Relative bioavailability (F) 
(Ratio of AUC(0-t) of TQ-PNC 




Groups ALT (U/L) ALP (U/L) AST (U/L) Bilirubin 
(mg/dl)
Albumin
Saline control 35.9±10.46 104.41±2.54 59.2±3.21 0.40±0.01 5.1±0.06
Toxic control (PCM) 87.0±6.49 386.1±5.54 102.73±5.65 2.39±0.01 3.2±0.08
TQ suspension 47.41±7.64 168.20±2.01 79.86±4.65 0.60±0.02 4.8±0.21
TQ-PNC 39.2±9.23 110±1.67 69.7±2.55 0.58±0.03 4.5±0.04
Silymarin 45.3±6.01 121.31±1.62 73.90±3.54 0.50±0.01 4.3±0.10
30 Values were the means of three replicate samples. The data were presented as mean ± SD (n=4), ap<0.001 vs saline control, 
31 bp<0.001 vs toxic control and cp<0.05 vs Silymarin
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